IGF-1 LR3 Therapy: Complete Guide
IGF-1 LR3 (Long R3 IGF-1) is a modified form of insulin-like growth factor 1, altered so that it binds far less to the IGF binding proteins that normally carry the hormone in circulation. It was developed as a laboratory reagent for cell culture, not as a human therapeutic, and it is not approved for human use anywhere. It is widely claimed online to last far longer than natural IGF-1. That has the pharmacology backwards: binding proteins are what prolong native IGF-1, so binding them less leaves more hormone immediately free and more potent in laboratory models, while animal work found it cleared from plasma faster than native IGF-1, not slower.
Fact-checking at PeptideProbe is editorial, not clinical. Our editors check claims, dosing figures, and trial results against primary sources; they are not licensed clinicians and do not provide medical review. Nothing here is medical advice — talk to a qualified healthcare provider before starting any therapy.
What is IGF-1 LR3?
IGF-1 LR3 (Long R3 IGF-1) is a modified form of insulin-like growth factor 1, altered so that it binds far less to the IGF binding proteins that normally carry the hormone in circulation. It was developed as a laboratory reagent for cell culture, not as a human therapeutic, and it is not approved for human use anywhere. It is widely claimed online to last far longer than natural IGF-1. That has the pharmacology backwards: binding proteins are what prolong native IGF-1, so binding them less leaves more hormone immediately free and more potent in laboratory models, while animal work found it cleared from plasma faster than native IGF-1, not slower.
How IGF-1 LR3 Works
IGF-1 LR3 works through specific biological pathways to produce its therapeutic effects. Consult with a qualified provider for detailed information about how this peptide therapy works for your specific condition.
Benefits & Uses
No approved therapeutic use. Native IGF-1 (mecasermin) is FDA-approved for severe primary IGF-1 deficiency, but that is a different molecule with different pharmacokinetics, and its approval does not extend to this analogue.
Clinical Evidence & Research
Clinical research on IGF-1 LR3 continues to evolve. IGF-1 LR3 has been studied in preclinical and clinical settings. Speak with your provider about the current evidence base.
Side Effects & Safety
Hypoglycaemia is the principal acute danger, because IGF-1 has insulin-like activity and this analogue circulates unbuffered by the binding proteins that normally restrain it. Because IGF-1 signalling promotes cell proliferation, there is a theoretical concern about growth of existing malignancies. This compound is sold as a research chemical and is not manufactured to pharmaceutical standards.
Dosing & Administration
Dosing protocols for IGF-1 LR3 should be determined by a qualified healthcare provider based on your individual health profile, treatment goals, and response to therapy. Self-dosing without medical supervision is not recommended.
Find IGF-1 LR3 Providers Near You
Search our directory for qualified providers offering IGF-1 LR3 therapy. Filter by location, telehealth, and more.
Browse ProvidersIGF-1 LR3 FAQ
No approved therapeutic use. Native IGF-1 (mecasermin) is FDA-approved for severe primary IGF-1 deficiency, but that is a different molecule with different pharmacokinetics, and its approval does not extend to this analogue.
Costs vary by provider and location. Contact providers directly for current pricing.
IGF-1 LR3 has an FDA status of "Research". It is currently used in research and clinical settings. Consult with a qualified provider about its regulatory status and appropriate use.
Hypoglycaemia is the principal acute danger, because IGF-1 has insulin-like activity and this analogue circulates unbuffered by the binding proteins that normally restrain it. Because IGF-1 signalling promotes cell proliferation, there is a theoretical concern about growth of existing malignancies. This compound is sold as a research chemical and is not manufactured to pharmaceutical standards.
PeptideProbe lists 0 providers offering IGF-1 LR3 therapy. Use our directory to search by location, filter by telehealth availability, and compare providers.
What IGF-1 LR3 is used for
Each of these reviews the evidence for that goal, including where it is weaker than the marketing suggests.
Stay Updated
Get notified when new peptide therapy providers join in your area.
Related Peptides
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.